Author Question: Which finding is a sign or symptom of hypothyroidism? 1. Anxiety 2. Bradycardia 3. Tachycardia ... (Read 101 times)

Beheh · **on:** Jul 23, 2018

Which finding is a sign or symptom of hypothyroidism?

1. Anxiety
2. Bradycardia
3. Tachycardia
4. Weight loss

Question 2

A teenage client is taking duloxetine (Cymbalta) for a generalized anxiety disorder. The dose has been changed by the physician. What adverse effects will the nurse advise the client and family to watch?

1. Warning signs of suicide
2. Irritability
3. Weight gain
4. Fatigue

Dnite · **Reply #1 on:** Jul 23, 2018

Answer to Question 1

2
Rationale 1: Anxiety is a symptom of hyperthyroidism.
Rationale 2: Bradycardia can be a more severe symptom of hypothyroidism.
Rationale 3: Tachycardia is symptom of hyperthyroidism.
Rationale 4: Weight loss is a sign of hyperthyroidism.
Global Rationale: Bradycardia can be a more severe symptom of hypothyroidism. Anxiety, tachycardia, and weight loss are symptoms of hyperthyroidism.

Answer to Question 2

1

Rationale 1:In 2004, the U.S. Food and Drug Administration (FDA) issued an advisory warning (black box warning) pointing out the potential warning signs of suicide in adults and children at the beginning of antidepressant therapy and when doses are changed.
Rationale 2:In 2004, the U.S. Food and Drug Administration (FDA) issued an advisory warning (black box warning) pointing out the potential warning signs of suicide in adults and children at the beginning of antidepressant therapy and when doses are changed.
Rationale 3:In 2004, the U.S. Food and Drug Administration (FDA) issued an advisory warning (black box warning) pointing out the potential warning signs of suicide in adults and children at the beginning of antidepressant therapy and when doses are changed.
Rationale 4:In 2004, the U.S. Food and Drug Administration (FDA) issued an advisory warning (black box warning) pointing out the potential warning signs of suicide in adults and children at the beginning of antidepressant therapy and when doses are changed.

Global Rationale: In 2004, the U.S. Food and Drug Administration (FDA) issued an advisory warning (black box warning) pointing out the potential warning signs of suicide in adults and children at the beginning of antidepressant therapy and when doses are changed. Irritability, weight gain, and fatigue are not black box warnings that must be watched for with this medication.